Lapatinib, trastuzumab or the combination added to preoperative chemotherapy for breast cancer: A meta-analysis of randomized evidence

Breast Cancer Research and Treatment

Volumn 135, Issue 3, 2012, Pages 655-662

  Valachis, Antonis ^a,b   Nearchou, Andreas ^b   Lind, Pehr ^b,c   Mauri, Davide ^d  

^a UPPSALA UNIVERSITY   (Sweden)

^b Department of Oncology ^*  (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d Panhellenic Association for Continual Medical Research PACMeR   (Greece)

Author keywords

Breast cancer; Lapatinib; Meta analysis; Neoadjuvant; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; PACLITAXEL; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIVER TOXICITY; META ANALYSIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PEER REVIEW; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN TOXICITY; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DIARRHEA; FEMALE; HUMANS; NEOADJUVANT THERAPY; PREOPERATIVE PERIOD; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 84866552915     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2189-z     Document Type: Review

References (28)

1. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14:68-320
2. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28:8-92
3. Valachis A, Mauri D, Polyzos NP, Chlouverakis G, Mavroudis D, Georgoulias V (2011) Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 20:485-490
4. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153
5. Harris CA, Ward RL, Dobbins TA, Drew AK, Pearson S (2011) The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. Ann Oncol 22:1308-1317
6. Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743 (Pubitemid 46021510)
7. Tagliabue E, Agresti R, Carcangiu ML et al (2003) Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 62: 33-527
8. Konecny GE, Pegram MD, Venkatesan N et al (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639 (Pubitemid 43259947)
9. Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188-194 (Pubitemid 40277368)
10. Chia S, Swain SM, Byrd DR, Mankoff DA (2008) Locally advanced and inflammatory breast cancer. J Clin Oncol 26:786-790 (Pubitemid 351264392)
11. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685 (Pubitemid 28363030)
12. Untch M, Fasching PA, Konecny GE et al (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29:3351-3357
13. Higgins JP, Altman DG, Gøtzsche PC, Cochrane Bias Methods Group et al (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Br Med J 343:d5928
14. Baselga J, Bradbury I, Eidtmann H, NeoALTTO Study Team et al (2012) Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:633-640
15. Untch M, Loibl S, Bischoff J, German Breast Group (GBG), Arbeitsgemeinschaft Gynäkologische Onkologie-Breast (AGOB) Study Group et al (2012) Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13:135-144
16. Guarneri V, Frassoldati A, Bottini A et al (2012) Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB Study. J Clin Oncol 30:1989-1995
17. Robidoux A, Tang G, Rastogi P et al (2012) Evaluation of lapatinib as a component of neoadjuvant therapy for HER2? operable breast cancer: NSABP protocol B-41. J Clin Oncol (suppl; abstr LBA506)
18. Holmes FA, Nagarwala YM, Espina VA et al (2011) Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. J Clin Oncol (suppl; abstr 506)
19. Alba E, Albanell J, de la Haba J et al (2011) Lapatinib vs trastuzumab in combination with standard EC-D chemotherapy in the neaodjuvant treatment of HER2? patients. Results from the GEICAM 2006-14 phase II randomized trial. Cancer Res 71(24 Suppl):559s-560s (Abstract nr PD07-04)
20. Wang YC, Morrison G, Gillihan R et al (2011) Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res 13:R121
21. Blackwell KL, Burstein HJ, Storniolo AM et al (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J Clin Oncol 30:2585-2592
22. Gianni L, Pienkowski T, Im YH et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25-32
23. Baselga J, Cortés J, Kim SB, CLEOPATRA Study Group et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119
24. Moy B, Goss PE (2007) Lapatinib-associated toxicity and practical management recommendations. Oncologist 12:756-765 (Pubitemid 47328219)
25. http://www.gsk.com/media/pressreleases/2011/2011-pressrelease-614837.htm. Accessed 20 June 2012
26. Gelmon KA, Boyle F, Kaufman B et al (2012) Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2? metastatic breast cancer: interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. J Clin Oncol 30:(suppl, abstr LBA671)
27. Weiner LM, Adams GP (2000) New approaches to antibody therapy. Oncogene 19:6144-6151 (Pubitemid 32059465)
28. Viloria-Petit A, Crombet T, Jothy S et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090-5101 (Pubitemid 32681540)